🚀 VC round data is live in beta, check it out!
Cormedix Valuation Multiples
Discover revenue and EBITDA valuation multiples for Cormedix and similar public comparables like Allogene Therapeutics, Boan Biotech, MeiraGTx, Fulcrum Therapeutics and more.
Cormedix Overview
About Cormedix
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company’s focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
Founded
2006
HQ
Employees
65
Website
Sectors
Financials (LTM)
EV
$662M
Cormedix Financials
Cormedix reported last 12-month revenue of $310M and EBITDA of $176M.
In the same LTM period, Cormedix generated $273M in gross profit, $176M in EBITDA, and $140M in net income.
Revenue (LTM)
Cormedix P&L
In the most recent fiscal year, Cormedix reported revenue of $312M and EBITDA of $195M.
Cormedix expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $310M | XXX | $312M | XXX | XXX | XXX |
| Gross Profit | $273M | XXX | $276M | XXX | XXX | XXX |
| Gross Margin | 88% | XXX | 88% | XXX | XXX | XXX |
| EBITDA | $176M | XXX | $195M | XXX | XXX | XXX |
| EBITDA Margin | 57% | XXX | 63% | XXX | XXX | XXX |
| EBIT Margin | 43% | XXX | 48% | XXX | XXX | XXX |
| Net Profit | $140M | XXX | $163M | XXX | XXX | XXX |
| Net Margin | 45% | XXX | 52% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Cormedix Stock Performance
Cormedix has current market cap of $569M, and enterprise value of $662M.
Market Cap Evolution
Cormedix's stock price is $7.22.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $662M | $569M | 0.0% | XXX | XXX | XXX | $2.07 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCormedix Valuation Multiples
Cormedix trades at 2.1x EV/Revenue multiple, and 3.8x EV/EBITDA.
EV / Revenue (LTM)
Cormedix Financial Valuation Multiples
As of April 6, 2026, Cormedix has market cap of $569M and EV of $662M.
Equity research analysts estimate Cormedix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cormedix has a P/E ratio of 4.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $569M | XXX | $569M | XXX | XXX | XXX |
| EV (current) | $662M | XXX | $662M | XXX | XXX | XXX |
| EV/Revenue | 2.1x | XXX | 2.1x | XXX | XXX | XXX |
| EV/EBITDA | 3.8x | XXX | 3.4x | XXX | XXX | XXX |
| EV/EBIT | 5.0x | XXX | 4.4x | XXX | XXX | XXX |
| EV/Gross Profit | 2.4x | XXX | 2.4x | XXX | XXX | XXX |
| P/E | 4.1x | XXX | 3.5x | XXX | XXX | XXX |
| EV/FCF | 4.3x | XXX | 3.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Cormedix Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Cormedix Margins & Growth Rates
Cormedix's revenue in the last 12 month declined by (3%).
Cormedix's revenue per employee in the last FY averaged $4.8M, while opex per employee averaged $1.9M for the same period.
Cormedix's rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cormedix's rule of X is 35% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Cormedix Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (3%) | XXX | (2%) | XXX | XXX | XXX |
| EBITDA Margin | 57% | XXX | 63% | XXX | XXX | XXX |
| EBITDA Growth | (34%) | XXX | (38%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 38% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 35% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $4.8M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 14% | XXX | 12% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 28% | XXX | 28% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 7% | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 40% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Cormedix Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Allogene Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Boan Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| MeiraGTx | XXX | XXX | XXX | XXX | XXX | XXX |
| Fulcrum Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Contineum Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cormedix M&A Activity
Cormedix acquired XXX companies to date.
Last acquisition by Cormedix was on XXXXXXXX, XXXXX. Cormedix acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Cormedix
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCormedix Investment Activity
Cormedix invested in XXX companies to date.
Cormedix made its latest investment on XXXXXXXX, XXXXX. Cormedix invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Cormedix
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Cormedix
| When was Cormedix founded? | Cormedix was founded in 2006. |
| Where is Cormedix headquartered? | Cormedix is headquartered in United States. |
| How many employees does Cormedix have? | As of today, Cormedix has over 65 employees. |
| Who is the CEO of Cormedix? | Cormedix's CEO is Joseph Todisco. |
| Is Cormedix publicly listed? | Yes, Cormedix is a public company listed on Nasdaq. |
| What is the stock symbol of Cormedix? | Cormedix trades under CRMD ticker. |
| When did Cormedix go public? | Cormedix went public in 2010. |
| Who are competitors of Cormedix? | Cormedix main competitors are Allogene Therapeutics, Boan Biotech, MeiraGTx, Fulcrum Therapeutics. |
| What is the current market cap of Cormedix? | Cormedix's current market cap is $569M. |
| What is the current revenue of Cormedix? | Cormedix's last 12 months revenue is $310M. |
| What is the current revenue growth of Cormedix? | Cormedix revenue growth (NTM/LTM) is (3%). |
| What is the current EV/Revenue multiple of Cormedix? | Current revenue multiple of Cormedix is 2.1x. |
| Is Cormedix profitable? | Yes, Cormedix is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Cormedix? | Cormedix's last 12 months EBITDA is $176M. |
| What is Cormedix's EBITDA margin? | Cormedix's last 12 months EBITDA margin is 57%. |
| What is the current EV/EBITDA multiple of Cormedix? | Current EBITDA multiple of Cormedix is 3.8x. |
| What is the current FCF of Cormedix? | Cormedix's last 12 months FCF is $154M. |
| What is Cormedix's FCF margin? | Cormedix's last 12 months FCF margin is 50%. |
| What is the current EV/FCF multiple of Cormedix? | Current FCF multiple of Cormedix is 4.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.